White and Williams Client Strikes Deal to Bring COVID-19 Treatment Drug to Market
White and Williams represented Canada-based anti-infective expert Appili Theraputics (Appili) in a development and commercialization deal in which Appili joins a consortium of global companies, including FUJIFILM Toyama Chemical Co., Ltd., Dr. Reddy’s Laboratories Ltd. and Global Response Aid, that are working cooperatively on the broad spectrum anti-viral therapy favipiravir (brand name Avigan) for the prevention and treatment of the novel coronavirus. Our client will lead the development efforts in the United States and Canada and will assist in the development in many other countries around the world (and in exchange for those efforts, Appili will receive a share of profits and net sales).
The transaction was an exercise in patience and nuance, as we started working on the transaction prior to “lock-down” in March, and continued through various twists and turns until closing. For Appili, the transaction was a “bet-the-company” deal, and we are proud that we could assist the business and clinical teams in realizing their goals of working with this promising new drug. The White and Williams team consisted of Ryan Udell and Adam Chelminiak on the corporate side, and Frank Bruno and Elizabeth Hecht on the intellectual property side.